Some states are set to receive fewer doses of monoclonal antibody treatments after the Biden administration switched the distribution system this week. Demand for monoclonal antibodies, used to treat non-hospitalized COVID-19 patients, has shot up in recent weeks, leading to what some officials have described as a shortage. The Biden administration tipped off states in early September that it was limiting distribution of the treatments before abruptly switching on Monday from letting sites directly order the doses to putting the federal government in charge of allocation to states, which can then choose where to send them. Some state officials say they weren’t notified of the change until late Monday, and that pending orders with AmerisourceBergen, the primary distributor in the old model, were being closed out. The Department of Health and Human Services (HHS) alerted Texas health officials “that the national supply has considerably decreased and states should expect lower amounts …